Category: Processing
-
Novonesis will invest €600 million in Indian enzyme production capacity. The Patalganga expansion is due online in 2030 and will serve food, beverage, biofuel, and household-care customers across growing regional markets.
-
Wageningen has secured funding to turn agricultural side-streams into proteins. The six-year VASCO programme combines separation, fermentation, product development, consumer research, and commercial work around underused crop residues.
-
IDAK has sold KADI as it concentrates on frozen bakery. The transaction returns the Swiss potato-products manufacturer to Invision ownership while its management retains continuity and a minority stake.
-
Grote is acquiring Turatti to broaden European food processing capability. The transaction adds Italian fresh-produce engineering, complete lines, automation, and service capacity to an expanding international equipment group.
-
Atria has secured €41 million for its Nurmo factory modernisation. The ten-year NIB financing supports an €82.4 million production and energy programme intended to transform convenience-food manufacturing at the Finnish site.
-
Purina has opened its most advanced US pet-food manufacturing facility. The $550 million Ohio plant combines automated storage, robotics, digital manufacturing, and advanced food-safety systems across 1.3 million square feet.
-
KAIST researchers have mapped barriers to industrialising microbial food production. The study argues that manufacturing readiness, downstream processing, market entry, and regulatory predictability will decide which fermentation technologies reach commercial scale.
-
Chobani plans major dairy manufacturing investment at its Pennsylvania campus. The $1.2bn five-year programme could add up to ten production lines, more than 900 jobs, and demand for over three billion pounds of local milk annually.
-
Fresh Factory completes Illinois consolidation as packaged production volumes rise. The manufacturer produced 14.6 million units in Q2 while absorbing residual ramp-up costs across its new two-site footprint.
-
ByHeart has advanced its restart plan after FDA review milestones. New testing, supplier qualification, sanitation measures, and preventive controls now sit at the centre of its post-outbreak manufacturing programme.